Latebreakers: Topical thrombin of human origin approved
Evithrom is indicated to stop minor bleeding from capillaries and small veins when control of bleeding by standard surgical techniques is ineffective or impractical.
The FDA has approved the first human thrombin in 53 years and the only product currently licensed in the U.S. Evithrom is indicated to stop minor bleeding from capillaries and small veins when control of bleeding by standard surgical techniques is ineffective or impractical. The product can be used with an absorbable gelatin sponge and should be applied to the surface of bleeding tissue. The topical thrombin is derived from human plasma and is an alternative to a bovine-derived thrombin product already on the market. Evithrom is manufactured by Omrix Biopharmaceuticals and will be distributed by Ethicon, a division of Johnson & Johnson Wound Management.
